# Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

> **NCT06784648** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **BioInvent International AB** · enrollment: 35 (estimated)

## Conditions studied

- Melanoma Metastatic
- Melanoma of Skin
- Melanoma BRAF V600E/K Mutated
- Melanoma Recurrent
- Melanoma Stage III or IV
- Melanoma
- Melanoma Negative for bRAF
- Melanoma Negative for nRAS
- Melanomas
- Uveal Melanoma, Metastatic

## Interventions

- **BIOLOGICAL:** pembrolizumab (KEYTRUDA®)
- **BIOLOGICAL:** BI-1607
- **BIOLOGICAL:** Ipilimumab (YervoyTM, 50 mg/10 mL solution)

## Key facts

- **NCT ID:** NCT06784648
- **Lead sponsor:** BioInvent International AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-11
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06784648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06784648, "Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06784648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*